H.R. 2851, Stop the Importation and Trafficking of Synthetic Analogues Act of 2017, Hearing Before the Subcommittee on Crime, Terrorism, Homeland Security, and Investigations of the Committee on the Judiciary, House of Representatives, One Hundred Fifteenth Congress, First Session, June 27, 2017   [open pdf - 1MB]

This testimony compilation is from the June 27, 2017 hearing, "H.R. 2851, Stop the Importation and Trafficking of Synthetic Analogues Act of 2017," before the U.S. House of Representatives Committee on the Judiciary. From the witness testimony of Demetra Ashley: "DEA [Drug Enforcement Administration] has become increasingly alarmed over the proliferation of illicit fentanyl and its analogues, which have been added to heroin and other illicit substances and have also been encountered as counterfeit tablets resembling controlled prescription drugs ('CPDs'). Fentanyl and fentanyl analogues are potent synthetic opioids which present a serious risk of overdose and death by those who misuse these substances. The yearly market for illegal non-medical prescription pain relievers is over 12.5 million people, and if fentanyl is introduced into even a small portion of that overall market, there is a likelihood that overdoses will increase. In addition, this drug can be absorbed through the skin or inhaled, which makes it particularly dangerous for public safety personnel who encounter the substance during the course of their daily operations. Fentanyl and fentanyl analogues represent the deadly convergence of the synthetic drug threat and current national opioid epidemic." Statements, letters, and materials submitted for the record include those of the following: Demetra Ashley, Robert Perez, Marcia Lee Taylor, Reta Newman, and Angela Pacheco.

Public Domain
Retrieved From:
United States House of Representatives Judiciary Committee: https://judiciary.house.gov/
Media Type:
Help with citations